Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.

Pharmaceutical

Stada Group

Peter Goldschmidt

Christos Gallis

Stéphane Jacqmin

Boris Doebler

Simone Berger

Christoph Dengler

Bryan Kim

Miguel Pagan Fernandez

Stephan Eder

Volker Sydow

Frank Staud

Yann Brun

The executive team at Stada Group has a history of experience in various industries, including pharmaceuticals, healthcare, and law. They have also been educated at some of the world's most prestigious universities, including Johns Hopkins University, EBS Universität für Wirtschaft und Recht, Johannes-Gutenberg Universität Mainz, and Harvard Business School.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Stada Group

Leadership Team

Board of Directors